Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

6.2K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.2K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

2.9K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
2.9K
Tumor Progression02:07

Tumor Progression

7.0K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.4K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.4K
The Tumor Microenvironment02:17

The Tumor Microenvironment

7.4K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.4K
Selectins01:25

Selectins

3.8K
Cell adhesion is  an essential aspect of multicellularity. While stable cell interactions usually occur between cells of the same type, transient cell interactions occur between cells of different tissue types, such as between neutrophils and endothelial cells. Selectins are one class of cell adhesion molecules (CAMs) that bind carbohydrate ligands to form transient cell adhesion. They are rod-like proteins with a long extracellular part of variable length ending with the lectin domain,...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of PI3K-p110α Inhibitor Alpelisib in the Differentiation and Effector Functions of M-CSF and GM-CSF Macrophages.

International journal of molecular sciences·2026
Same author

A Multidisciplinary Integrated Approach for the Identification and Characterization of the AMP Profile in <i>Hermetia illucens</i> Hemolymph.

Insects·2026
Same author

From Sea to Therapy: Development and Analytical Control of Recombinant Human CDKL5 Production in the Marine Bacterium <i>Pseudoalteromonas haloplanktis</i> TAC125.

Marine drugs·2026
Same author

Proteomic and degradomic signatures of extracellular matrix remodeling in calcific aortic valve stenosis.

Molecular medicine (Cambridge, Mass.)·2026
Same author

Decoding the microbial landscape of endometrial cancer: a case-control study.

BMC microbiology·2026
Same author

Trained Immunity in Autoimmunity: Friend, Foe, or Therapeutic Target?

Biomedicines·2026

Related Experiment Video

Updated: Dec 3, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

687

Osteopontin binds ICOSL promoting tumor metastasis.

Davide Raineri1,2, Chiara Dianzani3, Giuseppe Cappellano4,5

  • 1Dipartimento di Scienze della Salute, Interdisciplinary Research Center of Autoimmune Diseases-IRCAD, Università del Piemonte Orientale, 28100, Novara, Italy.

Communications Biology
|October 27, 2020
PubMed
Summary

Osteopontin (OPN) binds the immune checkpoint ICOSL, distinct from ICOS binding. This interaction promotes tumor cell migration and metastasis, suggesting new therapeutic targets.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.4K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.7K

Related Experiment Videos

Last Updated: Dec 3, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma
03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

687
Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines
06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

7.4K
Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

10.7K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Inducible T-cell costimulator ligand (ICOSL) and its receptor ICOS are key immune checkpoint molecules.
  • Their interaction mediates immune responses with implications for anti-tumor activity.
  • Osteopontin (OPN) is a pleiotropic cytokine involved in various physiological and pathological processes.

Purpose of the Study:

  • To identify novel ligands for ICOSL.
  • To investigate the functional consequences of OPN binding to ICOSL.
  • To explore the role of the ICOSL-OPN interaction in tumor progression.

Main Methods:

  • In vitro binding assays to confirm OPN as an ICOSL ligand.
  • Cell migration and anchorage-independent growth assays.
  • In vivo studies using the 4T1 breast cancer mouse model.

Main Results:

  • Osteopontin (OPN) was identified as a novel ligand for ICOSL, binding to a different domain than ICOS.
  • OPN binding to ICOSL induced a conformational change in OPN, exposing functional domains.
  • In vitro, OPN-ICOSL interaction promoted cell migration and inhibited anchorage-independent growth.
  • In vivo, OPN-triggered ICOSL signaling enhanced angiogenesis and tumor metastasis in a mouse breast cancer model.

Conclusions:

  • Osteopontin is a novel ligand for ICOSL, modulating its function beyond the known ICOS interaction.
  • The OPN-ICOSL axis plays a significant role in promoting tumor cell migration, angiogenesis, and metastasis.
  • Targeting the ICOSL-OPN interaction presents a potential therapeutic strategy for cancer treatment.